Guo J, Huang X, Dou L, Yan M, Shen T, Tang W, Li J (2022) Aging and aging-related diseases: from molecular mechanisms to interventions and treatments
The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action
In a rat model of DOCA-salt hypertension, vascular mitochondrial ROS production was markedly elevated, accompanied by the activation of other ROS sources
At our IV therapy clinic, each infusion therapy session is tailored to help with hydration, recovery, and overall wellness
A dual GLP-1/GIP receptor agonist does not antagonize glucagon at its receptor but may act as a biased agonist at the GLP-1 receptor
TB-500 and KPV remain unfeatured because no vetted online path exists